<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00173888</url>
  </required_header>
  <id_info>
    <org_study_id>920303</org_study_id>
    <nct_id>NCT00173888</nct_id>
  </id_info>
  <brief_title>Docetaxel Plus Cisplatin Followed by Gemcitabine Versus Gemcitabine Plus Cisplatin Followed by Docetaxel for Non-Small Cell Lung Cancer (NSCLC)</brief_title>
  <official_title>A Randomized Phase II Study of Weekly Docetaxel Plus Cisplatin Followed by Gemcitabine Versus Gemcitabine Plus Cisplatin Followed by Weekly Docetaxel in the Treatment of Advanced Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the 1-year treatment failure rate of two sequential&#xD;
      chemotherapy regimens: weekly docetaxel plus cisplatin followed by gemcitabine; and&#xD;
      gemcitabine plus cisplatin followed by weekly docetaxelã€‚&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lung cancer is the leading cause of cancer death in men and women worldwide. Shifting trends&#xD;
      in the incidence of lung cancer closely follow the patterns of cigarette smoking, although&#xD;
      other carcinogens have been implicated. Despite intensive treatment over the past several&#xD;
      decades, the 5-year lung-cancer survival rate remains a dismal 8-14%.&#xD;
&#xD;
      Chemotherapy is the primary therapy to patients with stage IIIB/IV disease, and most&#xD;
      investigators believe that treatment with a combination of two agents is the best first-line&#xD;
      treatment for stage IV NSCLC. In the late 1970s and 1980s, studies were conducted using&#xD;
      combinations of agents. Outcomes were improved and these agents were eventually incorporated&#xD;
      into clinical practice.&#xD;
&#xD;
      Weekly docetaxel is being studied in combination with other commonly used NSCLC&#xD;
      chemotherapeutic agents including carboplatin, navelbine, and gemcitabine. These combinations&#xD;
      are being studied in both first- and second-line settings. Second line chemotherapy with&#xD;
      docetaxel may affect survival (TAX 318, 1 year survival 37% vs. 11%). However, the optimal&#xD;
      sequence of chemotherapy was rarely explored. Weekly docetaxel may offer better tolerability&#xD;
      vs. 3-weekly schedule when combining docetaxel to cisplatin. Based upon these studied, we&#xD;
      choose weekly docetaxel in combination with cisplatin as our regimen. We expected the regimen&#xD;
      would be effective and well tolerated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2003</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary objective of this study is to evaluate the 1-year treatment failure rate of two sequential chemotherapy regimens.</measure>
    <time_frame>2003~2009</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the response rate for each regimen, the toxicity of each arm, and the duration of response</measure>
    <time_frame>2003~2009</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel, Cisplatin</intervention_name>
    <description>docetaxel 36mg/m2 IF 30 mins on day 1,8,15 cisplatin 75mg/m2 IF 2 hrs on day 15</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine, Cisplatin</intervention_name>
    <description>gemcitabine 1000mg/m2 IF 30mins on D 1,8,15, cisplatin 75mg/m2 IF 2 hrs on day 15</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologic or cytologic diagnosis of stage IIIB/IV NSCLC, no prior chemotherapy&#xD;
&#xD;
          -  Age &gt; 18 years and &lt; 75 years&#xD;
&#xD;
          -  WHO PS: 0,1&#xD;
&#xD;
          -  Unidimensional or bi-dimensional measurable disease&#xD;
&#xD;
          -  Neutrophils &gt; 1.5 109/l, Platelets &gt; 100 109/l, Hemoglobin &gt; 10g/dl, Total bilirubin &lt;&#xD;
             1.5 UNL, AST (SGOT) and ALT (SGPT) &lt; 2.5 UNL, Alkaline phosphatases &lt; 5 UNL; except in&#xD;
             presence of only bone metastasis and in the absence of any liver disorders&#xD;
&#xD;
          -  Creatinine &lt; 1 UNL, and creatinine clearance should be &gt; 60 ml/min.&#xD;
&#xD;
          -  Life expectancy &gt; 12 weeks&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant, or lactating patients&#xD;
&#xD;
          -  Known clinical brain or leptomeningeal involvement&#xD;
&#xD;
          -  Pre-existing motor or sensory neurotoxicity of a severity &gt; grade 1 by NCIC-CTG&#xD;
             criteria&#xD;
&#xD;
          -  CHF, angina or arrhythmias&#xD;
&#xD;
          -  History of significant neurological or psychiatric disorders&#xD;
&#xD;
          -  Active uncontrolled infection&#xD;
&#xD;
          -  Contraindication for the use of corticosteroids&#xD;
&#xD;
          -  Concurrent treatment with other experimental drugs within 30 days prior to study entry&#xD;
&#xD;
          -  Concurrent treatment with any other anti-cancer therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chih-Hsin Yang, M.D.,Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Oncology , National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ann-Lii Cheng, M.D.,Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Oncology , National Taiwan University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Oncology, National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <study_first_submitted>September 8, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <last_update_submitted>December 4, 2012</last_update_submitted>
  <last_update_submitted_qc>December 4, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 6, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Combination, Chemotherapy,non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

